News | January 09, 2026
Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Subscribe To Our Newsletter & Stay Updated
